Not a good buy right now for an impatient trader: price trend remains bearish (SMA_200 > SMA_20 > SMA_5) and MACD downside momentum is still expanding.
There is a possible short-term bounce setup (RSI_6 ~24.9 oversold + price sitting near key support ~23.13), but without Intellectia signals or a catalyst, the edge is weak.
Best stance: HOLD / wait for either (1) a clear reclaim of the pivot (~24.81) or (2) a clean support bounce with improving momentum; otherwise downside risk toward ~22.09 remains.
Technical Analysis
Trend/Momentum: Bearish structure with SMA_200 > SMA_20 > SMA_5; MACD histogram -0.333 and negatively expanding → selling pressure still building.
RSI: RSI_6 = 24.878 (oversold/washed-out), which can support a reflex bounce but is not a trend reversal signal by itself.
Levels: Support S1 = 23.126 (current pre-market ~23.28 is just above), next support S2 = 22.085. Resistance/pivot to beat: Pivot = 24.81, then R1 = 26.495.
Probabilistic near-term drift (pattern analogs): ~flat next day (+0.07%) but negative bias next week (-0.74%) and next month (-2.57%).
Positioning/Sentiment: Open Interest P/C = 0.41 is call-heavy (bullish tilt), while Volume P/C = 0.81 is closer to balanced but still slightly call-favored.
Activity: Today’s volume 114 is below 5D avg (120.6) and far below 10D avg (643.7), but open interest appears elevated vs 30D norms (today vs OI avg 30D = 132.35).
Volatility: 30D IV 80.38 vs HV 69.11 → options are pricing rich volatility; IV percentile ~50 (mid), with IV trending down vs 5D/10D IV averages (cooling but still high).
Takeaway: Options lean modestly bullish on positioning, but volatility is expensive and the tape doesn’t show strong upside momentum confirmation.
Technical Summary
Sell
9
Buy
5
Positive Catalysts
Oversold technical condition near S1 (~23.13) can trigger short-covering / bounce attempts.
Options open interest skew is call-heavy (P/C 0.41), suggesting some market participants are positioned for upside.
Fundamentals show strong top-line and margin improvement in the latest reported quarter.
Upcoming earnings: 2026-02-18 (After Hours) could act as a catalyst if results/guide surprise positively.
Neutral/Negative Catalysts
and any miss/guide-down could pressure shares.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: $216.833M, +113.38% YoY (strong growth).
Gross Margin: 68.03%, +55.68% YoY (meaningful improvement in profitability at the gross level).
Net Income: $24.325M, -126.33% YoY (major decline).
EPS: $0.08, -124.24% YoY.
Read-through: growth/margins improved, but bottom-line volatility remains a key overhang for near-term sentiment.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data was provided in the dataset, so a recent trend assessment isn’t available.
Wall Street-style pros (from available data): strong revenue growth and improved gross margins.
Wall Street-style cons (from available data): deteriorating net income/EPS and a technically bearish tape with no near-term catalyst.
Wall Street analysts forecast CAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAI is 37.6 USD with a low forecast of 30 USD and a high forecast of 45 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
Wall Street analysts forecast CAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAI is 37.6 USD with a low forecast of 30 USD and a high forecast of 45 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.250
Low
30
Averages
37.6
High
45
Current: 21.250
Low
30
Averages
37.6
High
45
Citi
Buy
upgrade
$34 -> $42
AI Analysis
2025-08-13
Reason
Citi
Price Target
$34 -> $42
AI Analysis
2025-08-13
upgrade
Buy
Reason
Citi raised the firm's price target on Caris Life Sciences to $42 from $34 and keeps a Buy rating on the shares. The firm views Caris Life's first quarter as a public company as strong and lifted estimates post the print.
BTIG
Mark Massaro
Buy
maintain
$38 -> $45
2025-08-13
Reason
BTIG
Mark Massaro
Price Target
$38 -> $45
2025-08-13
maintain
Buy
Reason
BTIG analyst Mark Massaro raised the firm's price target on Caris Life Sciences to $45 from $38 and keeps a Buy rating on the shares. The company reported a nearly unprecedented 31% revenue beat in its first quarter as a public company, driven primarily by higher-than-expected mix contribution from its MI Cancer Seek CDx, which carries a premium CMS rate of $8,455, the analyst tells investors in a research note. Caris seems to be holding firmly onto its market leadership in tissue therapy selection and estimates that the therapy selection market stands at just 30% overall penetration, the firm added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CAI
